 |
|
|
| |
Improved Hepatic Profile in Hepatitis C Virus (HCV) Genotype (GT) 4-Infected Egyptian Patients
With Compensated Cirrhosis Receiving Ombitasvir/Paritaprevir/Ritonavir With Ribavirin (AGATE-II)
|
| |
| |
Reported by Jules Levin
AASLD 2016 Nov 11-15 Boston, MA
EASL/2016
High SVR Rates in Patients With Genotype 4 Chronic Hepatitis C Infection and Compensated Cirrhosis Treated With Ombitasvir/Paritaprevir/Ritonavir Co-Administered With Ribavirin (AGATE-I) - (04/22/16)
Ombitasvir/Paritaprevir/Ritonavir With Ribavirin Achieves High Sustained Virologic Response (SVR) Rates in Egypti an Adults With Chronic HCV Genotype 4 Infection (AGATE-II) - (04/22/16)
Imam Waked1, Gamal E Esmat2, Rabab Fouad2, Naglaa Allam1, Mohamed Hassany3, Mohammad Mohey2, Ayman Yosry2, Gamal E Shiha4, Reham Soliman4, Marisol Marti nez5, Roula B Qaqish5, Colleen Hall5, Niloufar Mobashery5
1National Liver Institute, Menoufiya, Egypt; 2Cairo University, Cairo, Egypt; 3Nati onal Hepatology and Tropical Medicine Research Insti tute, Cairo, Egypt; 4Mansoura University and Egyptian Liver Research Institute and Hospital (ELRIAH), Mansoura, Egypt; 5AbbVie Inc., North Chicago, Illinois, United States
|
| |
|
|
|
|
|
